Acetylcholinesterase inhibitors AChEIs

In 1993 tacrine (9-amino-l,2,3,4-tetrahydroacridine, THA) was the first acetylcholinesterase inhibitor (AChEI) approved in the United States for the treatment of Alzheimer s disease (AD) (99TPS127). 

It appeared that cholinergic transmission performed other new functions. It can modulate various aspects of immune function, both innate and adaptive. Cholinergic transmission influences immune cell proliferation, cytokine production, differentiation of T-helper cells, and antigen presentation. These effects are mediated by cholinergic mAChR and nAQiR and other cholinergic components present in immune cells, for example, a7 nAQiR has the ability to induce anti-inflammatory activity [89]. This is probably one of the reasons why acetylcholinesterase inhibitors (AChEIs) act far broader than just to the inhibition of AChE. 

Acetylcholinesterase inhibitors (AChEIs), e.g. donepezil, galantamine, rivastigmine... 

---